Search Results
Search for other papers by R D Kineman in
Google Scholar
PubMed
Search for other papers by T W Gettys in
Google Scholar
PubMed
Search for other papers by L S Frawley in
Google Scholar
PubMed
Abstract
It is clear that dopamine (DA) at high concentrations (>100 nmol/l) inhibits the release of prolactin (PRL). Paradoxically, this monoamine at low concentrations (<10 nmol/l) has also been shown to augment PRL secretion. One possible explanation for these divergent effects is that DA binds receptors capable of interacting with multiple G protein subtypes that recruit opposing intracellular signaling pathways within lactotropes. To identify G proteins which couple DA receptor activation to PRL secretion, we have selectively immunoneutralized the activity of Giα3 and Gsα in primary cultures of rat pituitaries and subsequently tested the ability of these cultures to respond to high and low dose DA. Specifically, permeabilized pituitary cell cultures from random-cycling female rats were treated with control immunoglobulins (IgGs; 50 μg/ml) purified from preimmune serum (PII) or IgGs directed against the C-terminal portion of Giα3 or Gsα. After immunoneutralization of these G proteins, cells were challenged with 10 or 1000 nmol Da/l and the relative amount of PRL released was assessed by reverse hemolytic plaque assay. Results were expressed as % of basal values and compared. Under control conditions (PII), 1000 nmol DA/l inhibited (61·4 ±7·6% of basal values; mean ± s.e.m.) while 10 nmol DA/l augmented (120·0 ± 7·0%) PRL release in five separate experiments. Treatment of cells with anti-Giα3 attenuated the inhibitory effect of high dose DA (87·3 ± 14·5%). However, elimination of Giα3 activity did not significantly alter the PRL stimulatory effect of 10 nmol DA/l (121·0 ± 5·2%). Interestingly, immunoneutralization of Gsα resulted in a reciprocal shift in the activity of the lower dose of DA from stimulatory to inhibitory (69·7 ± 7·3%) while combined treatment of anti-Giα3 and anti-Gsα abrogated the responsiveness of pituitary cell cultures to either DA treatment (1000 nmol/l, 70·7 ± 12·5% and 10 nmol/l, 87·5 ± 21·4%). These data reveal that ligand-activated DA receptors can interact with both Giα3 and Gsα. Elimination of the stimulatory component (Gsα) favors the DA receptor activation of the inhibitory pathway (Giα3) suggesting a competition between negative and positive intracellular signaling mechanisms in normal lactotropes. In addition to DA treatment, we also challenged permeabilized pituitary cells with 100 nmol thyrotropin-releasing hormone (TRH)/1 as a positive control for secretory integrity. As anticipated, TRH stimulated PRL release to 188·0±31·0% of basal values under control conditions. Unexpectedly, immunoneutralization of Gsα completely blocked the ability of TRH to induce PRL release (101·8 ± 12·0% This neutralizing effect was specific to Gsα in that blockade of Giα3 activity had no significant effect on TRH-stimulated PRL release (166·2 ± 13·1%). These data are the first to support a direct role of Gsα in TRH signal transduction within PRL-secreting cells.
Journal of Endocrinology (1996) 148, 447–455
Search for other papers by J. A. Milne in
Google Scholar
PubMed
Search for other papers by A. S. I. Loudon in
Google Scholar
PubMed
Search for other papers by A. M. Sibbald in
Google Scholar
PubMed
Search for other papers by J. D. Curlewis in
Google Scholar
PubMed
Search for other papers by A. S. McNeilly in
Google Scholar
PubMed
ABSTRACT
Three experiments were conducted in the period between July and November with non-lactating red deer hinds to describe the effects of treatment with melatonin during this period on voluntary food intake (VFI), the onset of the breeding season, coat changes and plasma concentrations of prolactin and tri-iodothyronine (T3), and to examine whether prolactin mediated the observed effects.
In experiment 1, eight animals were treated orally each day with either 10 mg melatonin at 16.00 h or 10 mg melatonin at 16.00 h plus 10 mg domperidone (a dopamine antagonist) given twice daily for 120 days from July; eight animals were maintained as controls. In experiment 2, the same numbers of animals per treatment were used to compare treatments in which 10 mg melatonin or 20 mg bromocriptine (a dopamine agonist) were given orally each day at 16.00 h for 119 days from late June and compared with an untreated control group. In experiment 3, six animals were treated daily for 105 days from mid August with 5 mg domperidone given i.m. and compared with six control animals.
In experiments 1 and 2, the VFI of control animals reached a peak in late August and thereafter declined. Melatonin-treated animals showed a similar pattern but the peak in VFI was significantly (P<0·05) advanced by 2 weeks compared with controls, although the VFIs of both groups were similar in November. The mean date of onset of the breeding season of the melatonin-treated animals was advanced significantly (P < 0·05) by 23 days in both experiments and the coats of these animals had less undercoat and were pale coloured and patchy compared with the controls. The changes in VFI, coat and the onset of the breeding season were associated with the rapid decline in plasma prolactin concentration after the start of the melatonin treatment and significantly (P<0·01) lower plasma T3 concentrations than those of control animals.
In experiments 1 and 3, plasma prolactin concentrations in animals treated with domperidone were higher than those of controls for periods of 2–3 weeks. These short-term increases in plasma prolactin concentration were not associated with changes in VFI, coat or onset of the breeding season compared with controls.
In experiment 2, the pattern of decline in plasma prolactin concentrations was the same in bromocriptine-treated animals as in the melatonin-treated animals; plasma T3 concentrations were also similar in the two groups. The pattern of change in VFI over time in bromocriptine-treated animals was significantly (P<0·05) different from that of melatonin-treated animals and there was also a reduced amount and length of winter coat in the bromocriptine-treated animals. The mean date of onset of the breeding season in bromocriptine-treated animals was not significantly different from that of controls. It was concluded that a reduction in plasma prolactin concentration induced by bromocriptine produced different effects from that induced by melatonin treatment and that the effects of melatonin are unlikely to be induced through changes in contemporary plasma prolactin concentrations.
Journal of Endocrinology (1990) 125, 241–249
Search for other papers by Anthony Raffo in
Google Scholar
PubMed
Search for other papers by Kolbe Hancock in
Google Scholar
PubMed
Search for other papers by Teresa Polito in
Google Scholar
PubMed
Search for other papers by Yuli Xie in
Google Scholar
PubMed
Search for other papers by Gordon Andan in
Google Scholar
PubMed
Department of Medicine, Barnard College, Department of Surgery of Columbia University Medical Center, Department of Surgery, Institute of Genetics and Biophysics ‘Adriano Buzzati-Traverso’, Naomi Berrie Diabetes Center, Department of Medicine, BB 20-06, Columbia University Medical Center, 650 West 168th Street, New York, New York 10032, USA
Search for other papers by Piotr Witkowski in
Google Scholar
PubMed
Search for other papers by Mark Hardy in
Google Scholar
PubMed
Search for other papers by Pasquale Barba in
Google Scholar
PubMed
Search for other papers by Caterina Ferrara in
Google Scholar
PubMed
Department of Medicine, Barnard College, Department of Surgery of Columbia University Medical Center, Department of Surgery, Institute of Genetics and Biophysics ‘Adriano Buzzati-Traverso’, Naomi Berrie Diabetes Center, Department of Medicine, BB 20-06, Columbia University Medical Center, 650 West 168th Street, New York, New York 10032, USA
Search for other papers by Antonella Maffei in
Google Scholar
PubMed
Search for other papers by Matthew Freeby in
Google Scholar
PubMed
Search for other papers by Robin Goland in
Google Scholar
PubMed
Search for other papers by Rudolph L Leibel in
Google Scholar
PubMed
Search for other papers by Ian R Sweet in
Google Scholar
PubMed
Search for other papers by Paul E Harris in
Google Scholar
PubMed
2000 ). β-Cells of the endocrine pancreas also express dopamine receptors (D2) and respond to exogenous dopamine with inhibited glucose-stimulated insulin secretion ( Ahren & Lundquist 1985 , Niswender et al . 2005 , Rubi et al . 2005 , Shankar et
Centre for Neuroendocrinology and Department of Anatomy, Maurice Wilkins Centre for Molecular Biodiscovery, University of Otago, PO Box 913, Dunedin 9054, New Zealand
Search for other papers by David R Grattan in
Google Scholar
PubMed
catecholamine neurotransmitter, dopamine, rather than the more typical peptide hypothalamic hormones involved in regulating all other pituitary systems. Prolactin is also the only anterior pituitary hormone that does not have an endocrine target tissue, and
Department of Human Anatomy, Hebei Medical University, Shijiazhuang, People’s Republic of China
Search for other papers by Chunxiao Qi in
Google Scholar
PubMed
Search for other papers by Xiaoming Ji in
Google Scholar
PubMed
Search for other papers by Guoliang Zhang in
Google Scholar
PubMed
Search for other papers by Yunxiao Kang in
Google Scholar
PubMed
Search for other papers by Yuanxiang Huang in
Google Scholar
PubMed
Search for other papers by Rui Cui in
Google Scholar
PubMed
Search for other papers by Shuangcheng Li in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, People’s Republic of China
Search for other papers by Huixian Cui in
Google Scholar
PubMed
Department of Human Anatomy, Hebei Medical University, Shijiazhuang, People’s Republic of China
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, People’s Republic of China
Search for other papers by Geming Shi in
Google Scholar
PubMed
neurotransmissions. An imbalance in dopamine (DA) neurotransmissions leads to either hyperactive or hypoactive neuropsychiatric disorders ( Mehler-Wex et al . 2006 , Howes & Kapur 2009 , Leckman et al . 2010 , Chen et al . 2013 ). Elevation of DA, as a driver
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and University of Buenos Aires, V. Obligado 2490, 1428 Buenos Aires, Argentina
UVA Health System Charlottesville, Virginia, USA
Lawson Health Research Institute, London, Ontario, Canada
Center for the Study of Weight Regulation, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Isabel García-Tornadú in
Google Scholar
PubMed
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and University of Buenos Aires, V. Obligado 2490, 1428 Buenos Aires, Argentina
UVA Health System Charlottesville, Virginia, USA
Lawson Health Research Institute, London, Ontario, Canada
Center for the Study of Weight Regulation, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Marcelo Rubinstein in
Google Scholar
PubMed
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and University of Buenos Aires, V. Obligado 2490, 1428 Buenos Aires, Argentina
UVA Health System Charlottesville, Virginia, USA
Lawson Health Research Institute, London, Ontario, Canada
Center for the Study of Weight Regulation, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Bruce D Gaylinn in
Google Scholar
PubMed
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and University of Buenos Aires, V. Obligado 2490, 1428 Buenos Aires, Argentina
UVA Health System Charlottesville, Virginia, USA
Lawson Health Research Institute, London, Ontario, Canada
Center for the Study of Weight Regulation, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by David Hill in
Google Scholar
PubMed
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and University of Buenos Aires, V. Obligado 2490, 1428 Buenos Aires, Argentina
UVA Health System Charlottesville, Virginia, USA
Lawson Health Research Institute, London, Ontario, Canada
Center for the Study of Weight Regulation, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Edith Arany in
Google Scholar
PubMed
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and University of Buenos Aires, V. Obligado 2490, 1428 Buenos Aires, Argentina
UVA Health System Charlottesville, Virginia, USA
Lawson Health Research Institute, London, Ontario, Canada
Center for the Study of Weight Regulation, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Malcolm J Low in
Google Scholar
PubMed
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and University of Buenos Aires, V. Obligado 2490, 1428 Buenos Aires, Argentina
UVA Health System Charlottesville, Virginia, USA
Lawson Health Research Institute, London, Ontario, Canada
Center for the Study of Weight Regulation, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Graciela Díaz-Torga in
Google Scholar
PubMed
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and University of Buenos Aires, V. Obligado 2490, 1428 Buenos Aires, Argentina
UVA Health System Charlottesville, Virginia, USA
Lawson Health Research Institute, London, Ontario, Canada
Center for the Study of Weight Regulation, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Damasia Becu-Villalobos in
Google Scholar
PubMed
Introduction The dopamine D2 receptor (D2R) is the predominant dopamine-receptor subtype in the anterior pituitary and mediates dopamine’s inhibitory actions on lactotropes ( Missale et al. 1998 , Ben-Jonathan & Hnasko 2001
Search for other papers by E Y Faraoni in
Google Scholar
PubMed
Search for other papers by A I Abeledo Machado in
Google Scholar
PubMed
Search for other papers by P A Pérez in
Google Scholar
PubMed
Search for other papers by C A Marcial López in
Google Scholar
PubMed
Search for other papers by M A Camilletti in
Google Scholar
PubMed
Search for other papers by M Peña-Zanoni in
Google Scholar
PubMed
Search for other papers by S B Rulli in
Google Scholar
PubMed
Search for other papers by S Gutiérrez in
Google Scholar
PubMed
Search for other papers by G Díaz-Torga in
Google Scholar
PubMed
& Couldwell 2004 , Gillam et al. 2006 , Schlechte 2007 ). As the primary inhibitory control of prolactin synthesis and release is mediated by dopamine, the standard treatment for patients with prolactinoma is with dopamine agonists. Even though most
Radboud University Nijmegen Medical Centre, Department of Neurology, Laboratory of Pediatrics and Neurology, Nijmegen, The Netherlands
Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands
Department of Endocrinology, Andrology Unit, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
Search for other papers by Erik J Giltay in
Google Scholar
PubMed
Radboud University Nijmegen Medical Centre, Department of Neurology, Laboratory of Pediatrics and Neurology, Nijmegen, The Netherlands
Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands
Department of Endocrinology, Andrology Unit, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
Search for other papers by King H Kho in
Google Scholar
PubMed
Radboud University Nijmegen Medical Centre, Department of Neurology, Laboratory of Pediatrics and Neurology, Nijmegen, The Netherlands
Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands
Department of Endocrinology, Andrology Unit, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
Search for other papers by Ben A Blansjaar in
Google Scholar
PubMed
Radboud University Nijmegen Medical Centre, Department of Neurology, Laboratory of Pediatrics and Neurology, Nijmegen, The Netherlands
Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands
Department of Endocrinology, Andrology Unit, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
Search for other papers by Marcel M Verbeek in
Google Scholar
PubMed
Radboud University Nijmegen Medical Centre, Department of Neurology, Laboratory of Pediatrics and Neurology, Nijmegen, The Netherlands
Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands
Department of Endocrinology, Andrology Unit, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
Search for other papers by P Ben H Geurtz in
Google Scholar
PubMed
Radboud University Nijmegen Medical Centre, Department of Neurology, Laboratory of Pediatrics and Neurology, Nijmegen, The Netherlands
Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands
Department of Endocrinology, Andrology Unit, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
Search for other papers by Johanna M Geleijnse in
Google Scholar
PubMed
Radboud University Nijmegen Medical Centre, Department of Neurology, Laboratory of Pediatrics and Neurology, Nijmegen, The Netherlands
Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands
Department of Endocrinology, Andrology Unit, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
Search for other papers by Louis J G Gooren in
Google Scholar
PubMed
metabolizing these steroids ( Puy et al. 1995 , Poletti & Martini 1999 , Stoffel-Wagner 2003 , Altman 2004 ). Dopamine is synthesized from tyrosine by dopaminergic neurons, and is also the precursor to norepinephrine in noradrenergic nerves. Dopamine is
Search for other papers by A Sengupta in
Google Scholar
PubMed
Search for other papers by D K Sarkar in
Google Scholar
PubMed
characterized by seven transmembrane domains ( Baldwin 1994 , Gershengorn & Osman 1996 ). Dopamine (DA) is one of the hormones that play a key role in maintaining the normal function of lactotropes in the pituitary gland ( Freeman et al . 2000 , Ben
Search for other papers by Alejandra Abeledo-Machado in
Google Scholar
PubMed
Search for other papers by Pablo Anibal Pérez in
Google Scholar
PubMed
Search for other papers by María Andrea Camilletti in
Google Scholar
PubMed
Search for other papers by Erika Yanil Faraoni in
Google Scholar
PubMed
Search for other papers by Florencia Picech in
Google Scholar
PubMed
Search for other papers by Juan Pablo Petiti in
Google Scholar
PubMed
Search for other papers by Silvina Gutiérrez in
Google Scholar
PubMed
Search for other papers by Graciela Diaz-Torga in
Google Scholar
PubMed
rats presenting higher levels of serum prolactin compared to males since the first days of life. It is well known that dopamine is the primary hypothalamic inhibitor of prolactin synthesis and secretion (for review see Ben-Jonathan & Hnasko 2001